Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997-2013: a nationwide study

被引:7
作者
Mathiesen, Jes Sloth [1 ,2 ]
Kroustrup, Jens Peter [3 ]
Vestergaard, Peter [3 ,4 ]
Stochholm, Kirstine [5 ,6 ]
Paulsen, Per Logstrup [6 ]
Rasmussen, Ase Krogh [7 ]
Feldt-Rasmussen, Ulla [7 ]
Schytte, Sten [8 ]
Londero, Stefano Christian [8 ]
Pedersen, Henrik Baymler [9 ]
Hahn, Christoffer Holst [10 ]
Bentzen, Jens [11 ]
Moller, Soren [2 ,12 ]
Gaustadnes, Mette [13 ]
Rossing, Maria [14 ]
Nielsen, Finn Cilius [14 ]
Brixen, Kim [2 ]
Frederiksen, Anja Lisbeth [2 ,15 ]
Godballe, Christian [1 ]
机构
[1] Odense Univ Hosp, Dept ORL Head & Neck Surg & Audiol, JB Winslows Vej 4, DK-5000 Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Aalborg Univ Hosp, Dept Clin Med & Endocrinol, Aalborg, Denmark
[4] Steno Diabet Ctr North Jutland, Aalborg, Denmark
[5] Aarhus Univ Hosp, Dept Internal Med & Endocrinol, Aarhus, Denmark
[6] Aarhus Univ Hosp, Ctr Rare Dis, Aarhus, Denmark
[7] Copenhagen Univ Hosp, Dept Med Endocrinol, Copenhagen, Denmark
[8] Aarhus Univ Hosp, Dept ORL Head & Neck Surg, Aarhus, Denmark
[9] Aalborg Univ Hosp, Dept ORL Head & Neck Surg, Aalborg, Denmark
[10] Copenhagen Univ Hosp, Dept ORL Head & Neck Surg, Copenhagen, Denmark
[11] Herlev Hosp, Dept Oncol, Herlev, Denmark
[12] Odense Univ Hosp, OPEN, Odense, Denmark
[13] Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark
[14] Copenhagen Univ Hosp, Ctr Genom Med, Copenhagen, Denmark
[15] Odense Univ Hosp, Dept Clin Genet, Odense, Denmark
关键词
RET testing; medullary thyroid carcinoma; Denmark; ENDOCRINE NEOPLASIA 2B; CLINICAL-OUTCOMES; MUTATION; PROTOONCOGENE; CANCER; GUIDELINES; 2A; PREVALENCE; MANAGEMENT; DOMAIN;
D O I
10.2147/CLEP.S183268
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The completeness of REarranged during Transfection (RET) testing in patients with medullary thyroid carcinoma (MTC) was recently reported as 60%. However, the completeness on a population level is unknown. Similarly, it is unknown if the first Danish guidelines from 2002, recommending RET testing in all MTC patients, improved completeness in Denmark. We conducted a nationwide retrospective cohort study aiming to evaluate the completeness of RET testing in the Danish MTC cohort. Additionally, we aimed to access the completeness before and after publication of the first Danish guidelines and characterize MTC patients who had not been tested. Methods: The study included 200 patients identified from the nationwide Danish MTC cohort 1997-2013. To identify RET tested MTC patients before December 31, 2014, the MTC cohort was cross-checked with the nationwide Danish RET cohort 1994-2014. To characterize MTC patients who had not been RET tested, we reviewed their medical records and compared them with MTC patients who had been tested. Results: Completeness of RET testing in the overall MTC cohort was 87% (95% CI: 0.81-0.91; 173/200). In the adjusted MTC cohort, after excluding patients diagnosed with hereditary MTC by screening, completeness was 83% (95% CI: 0.76.-0.88; 131/158). Completeness was 88% (95% CI: 0.75-0.95; 42/48) and 81% (95% CI: 0.72-0.88) (89/110) before and after publication of the first Danish guidelines, respectively. Patients not RET tested had a higher median age at diagnosis compared to those RET tested. Median time to death was shorter in those not tested relative to those tested. Conclusion: The completeness of RET testing in MTC patients in Denmark seems to be higher than reported in other cohorts. No improvement in completeness was detected after publication of the first Danish guidelines. In addition, data indicate that advanced age and low life expectancy at MTC diagnosis may serve as prognostic indicators to identify patients having a higher likelihood of missing the compulsory RET test.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 39 条
[1]  
Amin M.B., 2017, AJCC CANC STAGING MA, VVIII ed.
[2]  
Andersen PH, 2002, LAEGEFORENINGENS FOR
[3]   Guidelines for diagnosis and therapy of MEN type 1 and type 2 [J].
Brandi, ML ;
Gagel, RF ;
Angeli, A ;
Bilezikian, JP ;
Beck-Peccoz, P ;
Bordi, C ;
Conte-Devolx, B ;
Falchetti, A ;
Gheri, RG ;
Libroia, A ;
Lips, CJM ;
Lombardi, G ;
Mannelli, M ;
Pacini, F ;
Pondder, BAJ ;
Raue, F ;
Skogseid, B ;
Tamburrano, G ;
Thakker, RV ;
Thompson, NW ;
Tomassetti, P ;
Tonelli, F ;
Wells, SA ;
Marx, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5658-5671
[4]   SINGLE MISSENSE MUTATION IN THE TYROSINE KINASE CATALYTIC DOMAIN OF THE RET PROTOONCOGENE IS ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B [J].
CARLSON, KM ;
DOU, SS ;
CHI, D ;
SCAVARDA, N ;
TOSHIMA, K ;
JACKSON, CE ;
WELLS, SA ;
GOODFELLOW, PJ ;
DONISKELLER, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1579-1583
[5]   Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrence [J].
Cho, Yoon Young ;
Jang, Hye Won ;
Jang, Ju Young ;
Kim, Tae Hyuk ;
Choe, Jun-Ho ;
Kim, Jung-Han ;
Kim, Jee Soo ;
Kim, Sun Wook ;
Chung, Jae Hoon .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 (10) :1501-1508
[6]   MUTATIONS IN THE RET PROTOONCOGENE ARE ASSOCIATED WITH MEN 2A AND FMTC [J].
DONISKELLER, H ;
DOU, SS ;
CHI, D ;
CARLSON, KM ;
TOSHIMA, K ;
LAIRMORE, TC ;
HOWE, JR ;
MOLEY, JF ;
GOODFELLOW, P ;
WELLS, SA .
HUMAN MOLECULAR GENETICS, 1993, 2 (07) :851-856
[7]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[8]  
Emmertsen K, 1984, Henry Ford Hosp Med J, V32, P238
[9]   POINT MUTATION WITHIN THE TYROSINE KINASE DOMAIN OF THE RET PROTOONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B AND RELATED SPORADIC TUMORS [J].
ENG, C ;
SMITH, DP ;
MULLIGAN, LM ;
NAGAI, MA ;
HEALEY, CS ;
PONDER, MA ;
GARDNER, E ;
SCHEUMANN, GFW ;
JACKSON, CE ;
TUNNACLIFFE, A ;
PONDER, BAJ .
HUMAN MOLECULAR GENETICS, 1994, 3 (02) :237-241
[10]  
Erichsen Rune, 2010, Clin Epidemiol, V2, P51